Press Release: October 10, 2001

WR Hambrecht + Co Initiates Coverage of IDX Systems (IDXC) with a Neutral Rating

San Francisco, CA, October 10, 2001—WR Hambrecht + Co today initiated research coverage on IDX Systems (IDXC) with a Neutral rating. WR Hambrecht’s Healthcare Services analyst Sean Wieland believes the company has a strong product but is hampered by poor visibility on future earnings growth. WR Hambrecht + Co offers all its research reports free and real time at www.wrhambrecht.com.

“IDX has achieved the distinction of having, by many accounts, the best product, and an extremely prestigious list of customers. However, it has fallen short of achieving industry-leading stature in the clinical products arena due to lackluster marketing efforts in the clinical arena,” Wieland said.

Wieland added, “Better visibility on future earnings is the key to driving shares of IDXC. To provide better visibility, we believe IDX needs to map out its marketing strategy for LastWord and specifically address scalability issues into smaller customers, an existing market which is currently dominated by Cerner.”

WR Hambrecht + Co estimates IDX Systems to post EPS of ($0.26) on revenues of $403.6 million in fiscal 2001 and $0.38 on $490.8 million in fiscal 2002. IDX Systems reported an EPS of ($1.28) on $341.9 million in fiscal 2000.

IDX Systems Corporation is a provider of information technology for physician groups, hospitals and integrated delivery networks.